CTOs on the Move

Disc Medicine

www.discmedicine.com

 
Disc Medicine is a clinical-stage biopharmaceutical company that is dedicated to transforming the lives of patients with hematologic disorders. We are building a portfolio of innovative, first-in-class therapeutic candidates that affect fundamental pathways of red blood cell biology. Disc Medicine is committed to developing treatments that empower and bring hope to the many patients who suffer from hematologic disease.
  • Number of Employees: 25-100
  • Annual Revenue: $1-10 Million

Executives

Name Title Contact Details

Funding

Disc Medicine raised $50M on 10/30/2019

Similar Companies

Hygiena

Hygiena is a Camarillo, CA-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

BioSkryb

Bioskryb is a venture-backed startup bringing new solutions for cellular heterogeneity, in both the research and clinical space studies, using a proprietary genome amplification system.

Genfit

GENFIT is a late-stage biopharmaceutical company dedicated to the discovery and development of innovative therapeutic and diagnostic solutions in metabolic and liver related diseases where there are considerable unmet medical needs, corresponding to a lack of approved treatments. GENFIT is a leader in the field of nuclear receptor-based drug discovery with a rich history and strong scientific heritage spanning almost two decades. Its most advanced drug candidate, elafibranor, is currently evaluated in pivotal Phase 3 clinical trial (“RESOLVE-IT”) as a potential treatment for nonalcoholic steatohepatitis, or NASH. NASH is considered by regulatory authorities as a medical emergency because of its potentially severe consequences, although often asymptomatic until late stages, and because its prevalence is on the rise. Elafibranor has also obtained positive preliminary results in a Phase 2 clinical trial in primary biliary cholangitis (PBC), a severe chronic liver disease. As part of GENFIT’s comprehensive approach to clinical management of NASH patients, the Company is also developing a new, non-invasive and easy-to-access blood-based in vitro diagnostic, or IVD, test to identify patients with NASH who may be appropriate candidates for drug therapy. With facilities in Lille and Paris, France, and Cambridge, MA, USA, the Company has approximately 170 employees. GENFIT is a public company listed on the Nasdaq Global Select Market and in compartment B of Euronext’s regulated market in Paris.

Xontogeny

Xontogeny is a life sciences accelerator that collaborates with entrepreneurs, scientific founders and first-time CEOs to drive the successful development of their technologies to enable new treatment options for patients with serious disease.

WHPM Biotech

WHPM Biotech is a Irwindale, CA-based company in the Healthcare, Pharmaceuticals, and Biotech sector.